The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2 - PubMed (original) (raw)
. 2009 May 15;77(10):1586-92.
doi: 10.1016/j.bcp.2009.02.018. Epub 2009 Mar 5.
Affiliations
- PMID: 19426695
- DOI: 10.1016/j.bcp.2009.02.018
The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2
Luke R E Harrison et al. Biochem Pharmacol. 2009.
Abstract
O(6)-Cyclohexylmethylguanine (NU2058) was developed as an inhibitor of CDK2 and was previously shown to potentiate cisplatin cytotoxicity in vitro. The aim of this study was to investigate the mechanism of cisplatin potentiation by NU2058. SQ20b, head and neck cancer cells were treated for 2h with NU2058 (100 microM) and then for a further 2h with cisplatin and NU2058. NU2058 increased cisplatin cytotoxicity, by clonogenic assay, with a dose modification factor (DMF) of 3.1. NU2058 increased total intracellular platinum levels 1.5-fold, and platinum-DNA adduct levels twofold. Furthermore, the cisplatin-DNA adducts formed were more toxic in the presence of NU2058. To investigate whether the effects of NU2058 on cisplatin adduct levels and toxicity were dependent on CDK2 activity, additional CDK2 inhibitors were tested. NU6230 (CDK2 IC(50) 18 microM) was equipotent to NU2058 (CDK2 IC(50) 17 microM) as a CDK2 inhibitor in cell-free and cell-based assays, yet did not potentiate cisplatin cytotoxicity. Furthermore, NU6102 was >1000-fold more potent than NU2058 as a CDK2 inhibitor (CDK2 IC(50) 5 nM) yet was no more active than NU2058 in potentiating cisplatin. NU2058 also potentiated melphalan (DMF 2.3), and monohydroxymelphalan (1.7), but not temozolomide or ionising radiation. Whilst NU2058 increased melphalan cytotoxicity, it did not increase melphalan-DNA adduct formation. These studies demonstrate that NU2058 alters the transport of cisplatin, causing more Pt-DNA adducts, as well as sensitizing cells to cisplatin- and melphalan-induced DNA damage. However, the effects of NU2058 are independent of CDK2 inhibition.
Similar articles
- Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity.
Fishel ML, Newell DR, Griffin RJ, Davison R, Wang LZ, Curtin NJ, Zuhowski EG, Kasza K, Egorin MJ, Moschel RC, Dolan ME. Fishel ML, et al. J Pharmacol Exp Ther. 2005 Jan;312(1):206-13. doi: 10.1124/jpet.104.073924. Epub 2004 Aug 10. J Pharmacol Exp Ther. 2005. PMID: 15304523 - STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM. Wang-Rodriguez J, et al. Laryngoscope. 2006 Aug;116(8):1409-16. doi: 10.1097/01.mlg.0000225895.40732.52. Laryngoscope. 2006. PMID: 16885745 - Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.
Tadesse S, Caldon EC, Tilley W, Wang S. Tadesse S, et al. J Med Chem. 2019 May 9;62(9):4233-4251. doi: 10.1021/acs.jmedchem.8b01469. Epub 2018 Dec 20. J Med Chem. 2019. PMID: 30543440 Review. - To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response.
Liu Q, Gao J, Zhao C, Guo Y, Wang S, Shen F, Xing X, Luo Y. Liu Q, et al. DNA Repair (Amst). 2020 Jan;85:102702. doi: 10.1016/j.dnarep.2019.102702. Epub 2019 Sep 16. DNA Repair (Amst). 2020. PMID: 31731257 Review.
Cited by
- DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study.
Xiao Z, Sun L, Zheng Y, Chen H, Zheng X, Luo J, Gu C, Lin R, Huang M, Bai Y, Chen ZS, Kinslow CJ, Loh J, Lin L. Xiao Z, et al. Transl Lung Cancer Res. 2022 Dec;11(12):2539-2566. doi: 10.21037/tlcr-22-746. Transl Lung Cancer Res. 2022. PMID: 36636408 Free PMC article. - Blockade of Nuclear β-Catenin Signaling via Direct Targeting of RanBP3 with NU2058 Induces Cell Senescence to Suppress Colorectal Tumorigenesis.
Zheng CC, Liao L, Liu YP, Yang YM, He Y, Zhang GG, Li SJ, Liu T, Xu WW, Li B. Zheng CC, et al. Adv Sci (Weinh). 2022 Dec;9(34):e2202528. doi: 10.1002/advs.202202528. Epub 2022 Oct 21. Adv Sci (Weinh). 2022. PMID: 36270974 Free PMC article. - Regulation and New Treatment Strategies in Breast Cancer.
Ferraiuolo RM, Wagner KU. Ferraiuolo RM, et al. J Life Sci (Westlake Village). 2019 Dec 12;1(3):23-38. J Life Sci (Westlake Village). 2019. PMID: 32095785 Free PMC article. - Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A, Cliby WA, Sarkaria J, Beale G, Edmondson RJ, Curtin NJ. Peasland A, et al. Br J Cancer. 2011 Jul 26;105(3):372-81. doi: 10.1038/bjc.2011.243. Epub 2011 Jul 5. Br J Cancer. 2011. PMID: 21730979 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous